Expert Insights on the Use of PCSK9 Inhibitors in Interventional Cardiology is organized by myCME.
Release Date: August 28, 2018
Expiration Date: August 28, 2019
This activity is intended for interventional cardiologists, cardiologists, vascular surgeons, cardiothoracic surgeons, technologists, and nurses involved in the management and treatment of patients with hyperlipidemia.
1.00 / AMA PRA Category 1 CreditTM
Treatment decisions for hyperlipidemia are increasingly challenging due to changing guidelines and a new class of therapies, the PCSK9 inhibitors. Further, clinicians must have competence in identifying high-risk patients who may require intensification or switching to a new therapy. Data from the cardiovascular outcomes trials with the PCSK9 inhibitors can assist in the identification of eligible at-risk patients. Interventional cardiologists require up-to-date knowledge of these new therapies and data since they are likely to encounter high-risk patients with hyperlipidemia.
Educational Objectives :
Upon completion of this activity, participants will be able to:
• Outline considerations in the selection of LDL cholesterol targets across diverse patient populations
• Compare and contrast study designs, endpoints, and results of cardiovascular outcomes clinical trials of the PCSK9 inhibitors
• Identify high-risk patients who may be candidates for a PCSK9 inhibitor
• Formulate individualized treatment strategies for complex patients based on available evidence
• Discuss strategies to overcome barriers and ensure appropriate use of PCSK9 inhibitors in interventional cardiology settings